A trial looking at adding new chemotherapy drugs to the standard treatment for ovarian cancer (GO-First)

Coronavirus (COVID-19)

We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.

Read about coronavirus and cancer

Cancer type:

Ovarian cancer




Phase 2

This trial was trying to find out if having gemcitabine and oxaliplatin before standard chemotherapy helped women with ovarian cancer.

If ovarian cancer cannot be completely removed with surgery, doctors use chemotherapy to try to control it. Two drugs that are very often used are paclitaxel and carboplatin (the standard treatment). In this trial, the researchers added two more drugs called oxaliplatin and gemcitabine.

The aims of the trial were to

  • See if having gemcitabine and oxaliplatin before paclitaxel and carboplatin worked better than the standard treatment
  • Learn more about the side effects

Summary of results

The researchers found that ovarian cancer responded to gemcitabine and oxaliplatin in more than three quarters of the women in this trial. But having all 4 drugs caused too many side effects.

The trial recruited 20 women who had stage 3 or 4 ovarian cancer. They all had 4 cycles of treatment with gemcitabine and oxaliplatin (GO), followed by 4 cycles of treatment with paclitaxel and carboplatin (PC).

After 4 cycles of GO, the researchers found

  • The cancer had disappeared in 4 women – researchers call this a complete response Open a glossary item
  • The cancer had got smaller in 12 women – researchers call this a partial response Open a glossary item

After 4 cycles of PC, there were

  • 13 complete responses
  • 4 partial responses

They also looked at how long it was before the cancer started growing again. On average, this was just over 1 year and 2 months.

Generally, the side effects of GO were not serious, but a small number of women had bad sickness, and a drop in white blood cells, causing an increased risk of infection. A quarter of the women had some nerve damage (peripheral neuropathy).

After having the PC chemotherapy, nearly three quarters of the women had peripheral neuropathy. So, the researchers say that having all 4 drugs causes too much nerve damage, and that this combination should not be used in future clinical trials.

We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (peer reviewed Open a glossary item) and published in a medical journal. The figures we quote above were provided by the trial team. We have not analysed the data ourselves.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Dr Peter Harper

Supported by

Guy's and St Thomas' NHS Foundation Trust

Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

Oracle 81

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Around 1 in 5 people take part in clinical trials

3 phases of trials

Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think